TC
CYTK icon

TFS Capital’s Cytokinetics CYTK Stock Holding History

TFS Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-95,987
Closed -$1.23M – 647
2017
Q1 		$1.23M Buy
+95,987
New +$1.12M 0.4% 36
2016
Q2 		– Sell
-122,027
Closed -$860K – 1002
2016
Q1 		$860K Buy
+122,027
New +$891K 0.12% 291
2015
Q4 		– Sell
-366,042
Closed -$2.45M – 777
2015
Q3 		$2.45M Sell
366,042
-533,909
-59% -$3.64M 0.24% 118
2015
Q2 		$6.05M Buy
899,951
+719,285
+398% +$4.72M 0.59% 9
2015
Q1 		$1.23M Buy
180,666
+112,156
+164% +$838K 0.12% 275
2014
Q4 		$549K Buy
68,510
+19,709
+40% +$84.6K 0.05% 553
2014
Q3 		$172K Buy
48,801
+31,277
+178% +$131K 0.01% 906
2014
Q2 		$84K Buy
+17,524
New +$107K 0.01% 1062
2014
Q1 		– Sell
-553,402
Closed -$3.6M – 1385
2013
Q4 		$3.6M Buy
553,402
+455,746
+467% +$2.99M 0.17% 173
2013
Q3 		$739K Buy
+97,656
New +$1.05M 0.03% 696

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

TFS Capital's CYTK Position: Q2 2017 in Review

TFS Capital sold out of Cytokinetics (CYTK) in Q2 2017, closing a stake of 95,987 shares — an estimated $1.23M sold.

TFS Capital first reported a position in CYTK in Q3 2013 and held it in 10 quarters. The position peaked at $6.05M in Q2 2015. 136 funds tracked by Wall St. Rank hold CYTK as of Q2 2017.

  • TFS Capital reported no remaining Cytokinetics position as of Q2 2017 after selling out during the quarter.
  • TFS Capital sold 95,987 Cytokinetics shares in Q2 2017, an estimated $1.23M.
  • TFS Capital first reported a position in Cytokinetics in Q3 2013 and held it in 10 quarters.
  • TFS Capital's Cytokinetics position peaked at $6.05M in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.